Aktuellt
SENASTE
Redeye provides a research update following the Q2 report published by Alzinova earlier today. The company reported a lower OPEX and capitalization than anticipated, however, the report did not include any major surprises. With an extended financial runway due to the recently announced rights issue, we argue that the main focus ahead will be to achieve a licensing deal. We reiterate our fair value range (SEK1 – SEK12) with a base case valuation of SEK6.5.
LÄS MER
